Consumer Non-Durables
Japan Tobacco Inc.
- 2,563.50 JPY
- -0.50
- -0.02%
Japan
Apr 19, 2019Ticker
TKS(2914)Prev. close
2,564Market cap (JPY)
5,148.00BMarket cap (USD)
46,011.52MShares
2,000M
In the news
- Bangladesh parties outbid each other promising growth Dec 26, 2018
- Stilted Japanese market ignites burst of overseas megadeals May 21, 2018
- Mitsubishi Corp. to abolish its special adviser system Apr 20, 2018
- Powerful incentives led to Japan's Finance Ministry document tampering Apr 8, 2018
- Japan companies hungry for more business experience on boards Mar 25, 2018 See more articles on Japan Tobacco Inc.
Business Summary
Japan Tobacco, Inc. engages in the manufacture and sale of tobacco, pharmaceutical and processed food products. It operates through the following segments: Japanese Domestic Tobacco, International Tobacco, Pharmaceutical, Processed Food, and Other. The Japanese Domestic segment deals with the production and sale of tobacco products in domestic areas. The International Tobacco segment manufactures and markets tobacco products worldwide. The Pharmaceutical segment develops, manufactures, and sells prescription drugs. The Processed Food segment offers processed food, bakery products and seasonings. The Other segment includes real estate and the handling of corporate expenses relating to corporate communication and operation of the head office. The company was founded on April 1, 1985 and is headquartered in Tokyo, Japan.
Financial Highlights
| Dec 2018 | JPY | USD |
| Revenue | 2,215.96B | 20,064.33M |
| Gross Profit | 1,195.57B | 10,825.28M |
| Operating income | 532,832M | 4,824.50M |
| Income before tax | 531,486M | 4,812.31M |
| Net income | 385,676M | 3,492.08M |
| EBITDA | 690,929M | 6,255.98M |
| Diluted EPS | 215.20 | 1.94 |
| Dividends Per Share | 150 | 1.35 |
| Total Assets | 5,461.40B | 49,778.06M |
| Total liabilities | 2,760.95B | 25,164.79M |
| Total equity | 2,630.59B | 23,976.61M |
| Operating cash flow | 461,389M | 4,177.62M |
| Currency in JPY | Currency in USD |
Historical Data
| Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | |
| Revenue | 2,871.95B | 2,252.88B | 2,143.28B | 2,139.65B | 2,215.96B |
| Gross Profit | 1,607.49B | 1,267.68B | 1,192.41B | 1,215.36B | 1,195.57B |
| Operating income | 743,190.14M | 591,831M | 535,001M | 526,027M | 532,832M |
| Income before tax | 659,314.35M | 558,732M | 571,748M | 538,532M | 531,486M |
| Net income | 483,890.79M | 398,454M | 421,695M | 392,409M | 385,676M |
| EBITDA | 904,732.40M | 730,032M | 675,146M | 670,864M | 690,929M |
| Diluted EPS | 279.19 | 270.37 | 235.33 | 218.97 | 215.20 |
| Dividends Per Share | 100 | 118 | 130 | 140 | 150 |
| Total Assets | 4,704.70B | 4,558.23B | 4,744.37B | 5,221.48B | 5,461.40B |
| Total liabilities | 2,082.20B | 2,036.71B | 2,216.33B | 2,379.45B | 2,760.95B |
| Total equity | 2,536.83B | 2,451.59B | 2,456.09B | 2,761.68B | 2,630.59B |
| Operating cash flow | 543,696M | 468,432M | 376,549M | 419,212M | 461,389M |
| Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | |
| Revenue | 27,132.29M | 18,608.90M | 19,724.90M | 19,081.27M | 20,064.33M |
| Gross Profit | 15,186.54M | 10,471.12M | 10,973.92M | 10,838.55M | 10,825.28M |
| Operating income | 7,021.16M | 4,888.54M | 4,923.67M | 4,691.07M | 4,824.50M |
| Income before tax | 6,228.76M | 4,615.14M | 5,261.86M | 4,802.58M | 4,812.31M |
| Net income | 4,571.47M | 3,291.24M | 3,880.90M | 3,499.47M | 3,492.08M |
| EBITDA | 8,547.30M | 6,030.09M | 6,213.44M | 5,982.71M | 6,255.98M |
| Diluted EPS | 2.63 | 2.23 | 2.16 | 1.95 | 1.94 |
| Dividends Per Share | 0.94 | 0.97 | 1.19 | 1.24 | 1.35 |
| Total Assets | 39,240.21M | 37,892.14M | 40,677.10M | 46,351.38M | 49,778.06M |
| Total liabilities | 17,366.88M | 16,930.97M | 19,002.29M | 21,122.55M | 25,164.79M |
| Total equity | 21,158.83M | 20,379.85M | 21,057.92M | 24,515.64M | 23,976.61M |
| Operating cash flow | 5,136.47M | 3,869.26M | 3,465.42M | 3,738.50M | 4,177.62M |
Valuation Measures
| Dec 2018 | |
| PER | 12.15 |
| ROA | 7.22% |
| ROE | 14.30% |
| Operating margin | 24.04% |
| Profit margin | 17.40% |
Key executives
- President, CEO & Representative Director: Masamichi Terabatake
- CFO, Representative Director & Executive VP: Naohiro Minami
- Executive Officer, Head-Research & Development: Hiroyuki Miki
- Director, Head-Compliance & General Affairs: Kazuhito Yamashita
- Representative Director, EVP & Head-Corporate: Kiyohide Hirowatari
Shareholders
- Government of Japan (33.3%)
- Japan Tobacco Inc. (11.3%)
- Nomura Asset Management Co., Ltd. (1.6%)
- The Vanguard Group, Inc. (1.5%)
- Mizuho Bank Pension Fund (1.1%)
- BlackRock Fund Advisors (0.9%)
- Daiwa Asset Management Co. Ltd. (0.8%)
- Nikko Asset Management Co., Ltd. (0.7%)
- Massachusetts Financial Services Co. (0.6%)
- DWS Investments (UK) Ltd. (0.5%)
Contact Details
- Website:http://www.jti.co.jp
- Address: 2-2-1 Toranomon, Minato-Ku, Tokyo, 105-8422, Japan
- Phone: +81.3.3582.3111
Related Companies
- JTI Business Services (Asia) Sdn. Bhd.
- JTI Processadora de Tabaco do Brasil Ltda.
- United Dhaka Tobacco Co. Ltd.
- PT Karyadibya Mahardhika
- PT Surya Mustika Nusantara
- JT International Financial Services BV
- Fluxo Brasil Distribuidora de Produtos SA
- Reynolds American, Inc. /Natural American Cigarettes 9/
- JTI Tutun Urunleri Sanayi AS
- JT International Group Holding BV
- Shanghai JS Foods Co. Ltd.
- Japan Tobacco (Hong Kong) Ltd.
- Logic Technology Development LLC
- JT International Co. Ukraine CJSC
- JTI Tutun Urunleri Pazarlama AS
- JT (UK) Ltd.
- Zandera Ltd.
- Al Nakhla Tobacco Free Zone SAE
- Batata SA /Subsdiaries (2)/
- Al Nakhla Tobacco Co. SAE
- JT International (Asia Pacific) Ltd.
- JT International (Philippines), Inc.
- Haggar Cigarette & Tobacco Factory Ltd. (South Sudan)
- Haggar Holding Co. /Sudan Cigarette & Tobacco Business (2)/
- National Tobacco Enterprise (Ethiopia) Share Co.
- JT International India Pvt Ltd.
- JT America, Inc.
- JT International Luxembourg SA
- JT International Hellas SA
- JT Financial Service Corp.
Competitors
- British American Tobacco p.l.c.
- Imperial Brands PLC
- Philip Morris International Inc.
- Altria Group Inc
- Ajinomoto Co., Inc.
- Maruha Nichiro Corp.
- Nichirei Corporation
- Nissui Pharmaceutical Co., Ltd.
- Abivax SA
- Electronic Cigarettes International Group Ltd.
- Pieris Pharmaceuticals, Inc.
- Swedish Match AB
- LT Group, Inc.
- 22nd Century Group, Inc.
- Akebia Therapeutics, Inc.
- Reata Pharmaceuticals, Inc. Class A
- FibroGen, Inc.
- Schweitzer-Mauduit International, Inc.
- JW Pharmaceutical Corporation
- NGM Biopharmaceuticals, Inc.
Copyright © 2019 FactSet Research Systems Inc. All rights reserved.
Last Updated on 19 Apr, 2019